GSK files for extended use of Relvar Ellipta in asthma
GlaxoSmithKline and Innoviva have applied to market Relvar Ellipta for extended use in patients with asthma who are already adequately controlled on inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy.
Read More
